RxDoctor Payments Data

Omer Ahmed, MD

Sleep Medicine · New York, NYNPI 1235387119

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Pharming Healthcare, Inc. at 29.4% of the total. 2025 is the largest year on record at $140, 9.3 times the $15 reported in 2019. That places this record below the midpoint for sleep medicine clinicians in NY, where the typical reported total is $1,050.

$325in general payments, 2019–2025

Across 10 payments — averaging $32.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharming Healthcare, Inc.$95
  • Regeneron Healthcare Solutions, Inc.$90
  • AbbVie$54
  • Stryker$27
  • Electromed, Inc.$23
  • Harmony Biosciences LLC$20
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$30995%
  • Education$155%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$325 in reported general payments places this provider in the 35th percentile of 81 sleep medicine providers in New York.

See all sleep medicine providers in New York

Medicare billing

Part B allowed, 2024
$128,088
Medicare patients
427
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,551
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,674
Spiriva RespimatTiotropium Bromide11$6,518
BelsomraSuvorexant11$4,568
Montelukast Sodium44$331
Zolpidem Tartrate38$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$15$12,67420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 81 sleep medicine providers in New York.

Other sleep medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →